07.28.10
Hospira 2Q
2Q Revenues: $968.2 million (+1%)
2Q Earnings: $83.5 million (+227%)
YTD Revenues: $2.0 billion (+9%)
YTD Earnings: $225.2 million (+18%)
Comments: Specialty Injectables sales in the quarter were $574.4 million (+17%), driven by U.S. sales of generic oncolytic oxaliplatin and Precedex. Other global Pharma revenues were $149.6 million (-16%). YTD Specialty Injectables sales were $1.2 billion (+29%). Other Pharma revenues were $295.7 million (-15%).
2Q Revenues: $968.2 million (+1%)
2Q Earnings: $83.5 million (+227%)
YTD Revenues: $2.0 billion (+9%)
YTD Earnings: $225.2 million (+18%)
Comments: Specialty Injectables sales in the quarter were $574.4 million (+17%), driven by U.S. sales of generic oncolytic oxaliplatin and Precedex. Other global Pharma revenues were $149.6 million (-16%). YTD Specialty Injectables sales were $1.2 billion (+29%). Other Pharma revenues were $295.7 million (-15%).